Abivax SA (DE:2X1)
XETRA:2X1
2X1 Stock Chart & Stats
€94.20
-€0.05(-0.72%)
At close: 4:00 PM EST
€94.20
-€0.05(-0.72%)
Day’s Range― - ―
52-Week Range€4.58 - €132.20
Previous CloseN/A
Volume500.00
Average Volume (3M)891.00
Market Cap
€7.41B
Enterprise Value€6.93B
Total Cash (Recent Filing)€530.38M
Total Debt (Recent Filing)€32.09M
Price to Earnings (P/E)―
Beta0.21
Next Earnings
Jun 08, 2026EPS Estimate
-0.81Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.04
Shares Outstanding79,167,435
10 Day Avg. Volume1,388
30 Day Avg. Volume891
Financial Highlights & Ratios
PEG Ratio-0.34
Price to Book (P/B)18.39
Price to Sales (P/S)0.00
P/FCF Ratio-51.60
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€130.00Price Target Upside38.00% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)-3.32
Revenue Forecast (FY)€3.40M
Bulls Say, Bears Say
Bulls Say
Improved Balance Sheet / Low LeverageA materially stronger 2025 balance sheet with debt at roughly 7% of equity increases financial flexibility and reduces near-term refinancing risk. For a clinical-stage biotech, this durable improvement supports continued R&D spending and partner negotiations over the next 2–6 months without immediate liquidity distress.
Broad Clinical Evidence For Lead AssetA sizable body of preclinical and clinical data (22 ECCO abstracts) showing mechanism support (miR-124 upregulation), anti-fibrotic potential, rapid symptomatic relief and a favorable safety profile strengthens the long-term probability of successful development or partnering across IBD indications, enhancing program durability beyond any single trial.
Differentiated Oral Product ProfileObefazimod’s oral small‑molecule profile and differentiated efficacy/safety signals offer structural commercial advantages versus injectable biologics: easier patient uptake, lower administration burden, and stronger partner interest. These attributes persistently improve market positioning if clinical outcomes remain favorable.
Bears Say
Persistent Cash BurnSustained large negative free cash flow (~-162M in 2025) means the company cannot self‑fund operations long term. This structural cash burn forces repeated financing, increasing dilution risk and potentially constraining program pace or scope if capital markets tighten, which materially affects long‑run strategy execution.
No Commercial Revenue In 2025Zero reported revenue in 2025 underscores lack of commercial traction and reliance on clinical/partnership milestones. Without product sales, durable profitability depends wholly on successful late‑stage outcomes or deals, extending time to self‑sustaining cash generation and raising execution risk over the coming months.
Reliance On External Financing / Balance Sheet SwingsHistorical swings in leverage (very high in 2022, elevated in 2024) point to dependence on capital raises or restructuring to fund operations. That structural reliance increases vulnerability to adverse financing conditions and potential dilutive financing, which can impact program timelines, partner negotiations, and long‑term shareholder value.
Abivax SA News
2X1 FAQ
What was Abivax SA’s price range in the past 12 months?
Abivax SA lowest stock price was €4.58 and its highest was €132.20 in the past 12 months.
What is Abivax SA’s market cap?
Abivax SA’s market cap is €7.41B.
When is Abivax SA’s upcoming earnings report date?
Abivax SA’s upcoming earnings report date is Jun 08, 2026 which is in 68 days.
How were Abivax SA’s earnings last quarter?
Abivax SA released its earnings results on Mar 23, 2026. The company reported -€1.04 earnings per share for the quarter, beating the consensus estimate of -€1.161 by €0.121.
Is Abivax SA overvalued?
According to Wall Street analysts Abivax SA’s price is currently Undervalued.
Does Abivax SA pay dividends?
Abivax SA does not currently pay dividends.
What is Abivax SA’s EPS estimate?
Abivax SA’s EPS estimate is -0.81.
How many shares outstanding does Abivax SA have?
Abivax SA has 79,167,435 shares outstanding.
What happened to Abivax SA’s price movement after its last earnings report?
Abivax SA reported an EPS of -€1.04 in its last earnings report, beating expectations of -€1.161. Following the earnings report the stock price went down -3.937%.
Which hedge fund is a major shareholder of Abivax SA?
Currently, no hedge funds are holding shares in DE:2X1
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Abivax SA
ABIVAX Société Anonyme discovers and optimizes drugs for the treatment of inflammatory diseases, infectious diseases, and cancer in France. Its principal products include ABX464 that is in Phase IIb clinical trials for the treatment of ulcerative colitis and Crohn's Disease, as well as for COVID-19; Phase IIa clinical trial for the treatment of rheumatoid arthritis diseases; and has completed Phase IIa clinical trial for the treatment of viral remission in patients with HIV. It also develops ABX 196, an immune enhancer candidate that is in Phase 1/2 clinical trials for the treatment of hepatocellular cancer. In addition, the company engages in the research programs for the treatment of Dengue fever, influenza, and respiratory syncytial virus. ABIVAX Société Anonyme has license contracts with the French National Centre for Scientific Research, the University of Montpellier, and the Institut Curie. The company was incorporated in 2013 and is headquartered in Paris, France.
2X1 Stock 12 Month Forecast
Average Price Target
€130.00
▲(38.00% Upside)
Technical Analysis
Options Prices
Currently, No data available
---